Healthcare / Drug Manufacturers - GeneralSão Paulo
$151.37
-5.69 (-3.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $7.3B · quality 81.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.41T
P/E
27.1x
↑EV/EBITDA
146.7x
↑ROE
21.0%
↑Gross Margin
81.9%
↑Debt/Equity
0.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.8%
FCF CAGR
+6.2%
FCF margin
14.8%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $58.74B · net income $10.22B · FCF $8.67B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $58.74B | $58.74B | $54.07B | $45.81B | $44.35B |
| Net Income | $10.22B | $10.22B | $7.04B | $5.96B | $3.29B |
| EBITDA | $19.51B | $19.51B | $15.44B | $13.42B | $9.09B |
| EPS | 0.55 | 0.55 | 0.38 | 0.32 | 0.18 |
| Gross Margin | 81.9% | 81.9% | 81.1% | 82.0% | 72.1% |
| Operating Margin | 22.7% | 22.7% | 19.0% | 19.0% | 10.2% |
| Net Margin | 17.4% | 17.4% | 13.0% | 13.0% | 7.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.60 | 0.60 | 0.74 | 0.73 | 0.79 |
| Current Ratio | 0.91 | 0.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $8.67B | $8.67B | $7.28B | $6.57B | $7.24B |
| Returns | |||||
| ROE | 21.0% | 21.0% | 17.2% | 15.2% | 8.9% |
| Valuation | |||||
| P/E | 27.08 | 27.08 | 360.16 | 351.12 | 703.85 |
| EV/EBITDA | 146.66 | 146.66 | 165.68 | 157.36 | 257.54 |
| P/B | 58.30 | 58.30 | 62.11 | 53.38 | 62.55 |
| Growth & Yield | |||||
| Revenue Growth | 8.6% | 8.6% | 18.0% | 3.3% | — |
| EPS Growth | 45.3% | 45.3% | 18.1% | 80.6% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
191.0%
EPS terminal req.
$13.43
Spread vs growth
-145.7%
5Y implied EPS CAGR
97.2%
EPS terminal req.
$16.25
Spread vs growth
-51.9%
10Y implied EPS CAGR
47.3%
EPS terminal req.
$26.17
Spread vs growth
-1.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.1%
Start / end P/E
353.1x → 277.7x
EPS bridge
0.38 → 0.55
Residual
-9.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.